Kyverna Therapeutics

Inspection Readiness Project Manager (Contract)

Kyverna Therapeutics  •  $80 - $100/hr  •  Remote  •  18 hours ago
Apply
AI can make mistakes so check important info. Chat history is never stored.

Job Description

Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefine what’s possible.

We are seeking a highly experienced Inspection Readiness Project Manager to drive enterprise-wide inspection readiness, remediation, and quality system execution across clinical programs. This individual will serve as the central orchestrator across Clinical Operations, Quality, Regulatory, and external partners to ensure continuous state of inspection readiness for global health authority inspections (e.g., FDA, EMA).

This role requires deep expertise in GxP environments, strong clinical development knowledge, and a proven ability to drive complex, cross-functional initiatives under tight timelines.

Title: Inspection Readiness Project Manager

Location: Remote. West coast highly preferred

Duration: 6+ months

Hourly rate: $80-$100/hr

Responsibilities

    • Lead and maintain a global inspection readiness processes, timelines, and activities
    • Collaborate closely with Kyverna QA, Clin Ops, Safety, Biometrics and other functions as needed to develop, align and drive inspection readiness remediation activities.
    • Partner with Inspection readiness taskforce to define and operationalize inspection readiness frameworks, playbooks, and governance models
    • Establish inspection simulation strategies, including mock audits and risk assessments
    • Own end-to-end remediation planning and execution following audits/inspections
    • Track and manage inspection findings, risks, and commitments through centralized dashboards
    • Escalate risks proactively and implement mitigation strategies
    • Build and manage integrated, cross-functional project plans with clear milestones and dependencies
    • Drive accountability across stakeholders to meet critical timelines and deliverables
    • Develop resource plans to support inspection readiness and remediation activities
    • Partner with Quality to develop, refine, and implement SOPs, work instructions, and procedural documentation
    • Ensure processes are aligned with GCP (Good Clinical Practice) and broader GxP requirements
    • Influence without authority to drive execution across a matrixed organization

Qualifications

  • Bachelor’s degree required; advanced degree (MS, PhD, MBA) preferred
  • 10+ years in biotech/pharma with experience in inspection readiness and remediation programs is a must
  • Strong exposure to GCP, GxP, and global inspections
  • Deep understanding of clinical trial processes, quality systems, and regulatory expectations
  • Expertise in audit/inspection processes preferred
  • Exceptional program management skills (complex, global, cross-functional initiatives)
  • Ability to drive execution under pressure and tight regulatory timelines
  • Strong stakeholder management and executive communication skills
  • Experience in cell and gene therapy or other complex modalities strongly preferred
  • Background in building or scaling inspection readiness programs from scratch
  • Familiarity with clinical trial systems (e.g., TMF platforms, QMS tools)
Kyverna Therapeutics

About Kyverna Therapeutics

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.

Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

Industry
Biotech & Life Sciences
Company Size
51-200 employees
Headquarters
Emeryville, California
Year Founded
2018
Social Media